← Eichor
Condition: Immune Checkpoint Inhibitors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Immune Checkpoint Inhibitors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalised Immunotherapy Platform
Phase N/A · 3 location(s) · Melanoma Institute Australia · NCT06536257Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT06864481A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperth
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06685887Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibi
Phase N/A · 6 location(s) · Shantou University Medical College · NCT07357636A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves T
Phase 1 · 11 location(s) · AbbVie · NCT06487559Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06446154The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line
Phase 2 · 1 location(s) · Zhejiang University · NCT07257653Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
Phase N/A · 1 location(s) · Hanneke W. M. van Laarhoven · NCT06519292Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06694454A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plu
Phase 1/Phase 2 · 1 location(s) · Yinghua Xu · NCT07495215Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
NA · 1 location(s) · Goethe University · NCT07161310Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06607120TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC
Phase 2 · 1 location(s) · Fudan University · NCT06914297An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
NA · 1 location(s) · Peking Union Medical College Hospital · NCT07452003The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Phase N/A · 1 location(s) · VastBiome · NCT05037825Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT04892849ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer
Phase 2 · 2 location(s) · Soroka University Medical Center · NCT05502913Electroacupuncture Combined With PD-1 Inhibitor for ECOG2 Advanced NSCLC
NA · 1 location(s) · Kong Fanming · NCT07239661Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
Phase 1/Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06759064Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
NA · 1 location(s) · Jules Bordet Institute · NCT06107608TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer
NA · 1 location(s) · Karl Landsteiner University of Health Sciences · NCT07423169Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metast
Phase 2 · 1 location(s) · Yale University · NCT04974671TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06487663Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
Phase N/A · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06899789Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Mon
Phase 3 · 36 location(s) · ImmunityBio, Inc. · NCT06745908Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
NA · 1 location(s) · Ruijin Hospital · NCT05552846A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.